Cargando…
Impact of ERT and follow-up of 17 patients from the same family with a mild form of MPS II
BACKGROUND: Mucopolysaccharidosis type II, also known as Hunter syndrome, is a rare X-linked recessive disorder caused by deficiency of the lysosomal enzyme Iduronate-2- Sulfatase (IDS), leading to progressive accumulation of Glycosaminoglycans (GAGs) in several organs. Over the years, Enzyme Replac...
Autores principales: | Stephan, Bruno de Oliveira, Quaio, Caio Robledo, Spolador, Gustavo Marquezani, de Paula, Ana Carolina, Curiati, Marco Antônio, Martins, Ana Maria, Leal, Gabriela Nunes, Tenorio, Artur, Finzi, Simone, Chimelo, Flavia Teixeira, Matas, Carla Gentile, Honjo, Rachel Sayuri, Bertola, Debora Romeo, Kim, Chong Ae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326110/ https://www.ncbi.nlm.nih.gov/pubmed/35882106 http://dx.doi.org/10.1016/j.clinsp.2022.100082 |
Ejemplares similares
-
A clinical follow-up of 35 Brazilian patients with Prader-Willi Syndrome
por: Quaio, Caio Robledo D'Angioli Costa, et al.
Publicado: (2012) -
Tegumentary manifestations of Noonan and Noonan-related syndromes
por: Quaio, Caio Robledo D'Angioli Costa, et al.
Publicado: (2013) -
Detection of deletions at 7q11.23 in Williams-Beuren syndrome by polymorphic markers
por: Dutra, Roberta Lelis, et al.
Publicado: (2011) -
Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series
por: Lampe, Christina, et al.
Publicado: (2014) -
Safety outcomes and patients’ preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond
por: Toscano, Antonio, et al.
Publicado: (2023)